Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $29.4552W HIGH $60.91
Volume
183.57 K
Value Traded
35.36 M
Short % Float
12.9%
Days to Cover
5.9
+11.03%Week
+7.52%1 Month
-12.55%3 Month
+43.66%6 Month
+18.59%5 Year
+246.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.90 B
EPS (TTM)
1.42
P/E Ratio
34.15
Ent. Value
3.42 B
Total Shares
80.39 M
Float Shares
78.92 M
Insiders
1.83%
Institutions
114.12%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VCYT Catalyst Timeline
Dated clinical, regulatory and corporate events for Veracyte, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veracyte, Inc.
114Total events
0Upcoming
14Tier-1 (high impact)
2014 to 2026Coverage
Event history 50
▲Oral PresentationPresentation
ENZAMET trial results presented at ASCO 2026 showing Decipher Prostate identifies chemotherapy benefit in metastatic prostate cancer
metastatic prostate cancersource ↗
▲Oral PresentationProsignaPresentation
OPTIMA trial results presented at ASCO Annual Meeting
early-stage, ER-positive HER2-negative breast cancersource ↗
◆Oral PresentationPresentation
ENZAMET trial results presentation at ASCO 2026
metastatic hormone-sensitive prostate cancersource ↗
▲Topline ReadoutProsignaClinical Data
OPTIMA trial topline results announced
early-stage, ER-positive HER2-negative breast cancersource ↗
◆Oral PresentationTrueMRDPresentation
Oral presentation of TrueMRD MIBC test data in HCRN GU 20-444 trial at ASCO GU
muscle-invasive bladder cancersource ↗
◆Poster PresentationPresentation
Poster presentation of biomarker results from Bladder Cancer Prognosis Programme with Decipher Bladder
non-muscle invasive bladder cancersource ↗
◆Poster PresentationPresentation
Poster presentation on transcriptomic characterization of prostate cancer in HIV patients using Decipher Prostate
prostate cancersource ↗
◆Oral PresentationPresentation
Veracyte management presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchTrueMRDPost-Market
Planned availability of TrueMRD MIBC test to clinicians
muscle-invasive bladder cancersource ↗
◆Quarterly UpdateCorporate
Full audited Q4 and 2023 financial results earnings call in February 2024
◆AcquisitionCorporate
Definitive agreement to acquire C2i Genomics for $70M in shares plus up to $25M milestones
▲Quarterly UpdateCorporate
Preliminary full-year 2023 revenue of $358-$359 million, 21% growth
▼Equity OfferingCorporate
Pricing of upsized public offering of 7,432,433 shares at $74.00 per share
◆Oral Presentationnasal swab testPresentation
Preliminary data for noninvasive nasal swab test for lung cancer early detection
lung cancer early detectionsource ↗
▲Partnership / LicenseCorporate
Collaboration with Johnson & Johnson to develop interventions for lung cancer
lung cancersource ↗
▲Quarterly UpdateCorporate
Expects to achieve operating cash flow breakeven before end of 2019
▲FDA Feedback ReceivedFDA Meeting
Received draft Medicare coverage for Envisia Genomic Classifier
idiopathic pulmonary fibrosissource ↗
▲Quarterly UpdateCorporate
Increased 2018 revenue guidance to $87-89M, narrowed cash burn guidance to $18-21M
▲Other Regulator MilestoneEx-US Regulatory
Positioned to gain Medicare coverage in 2018
idiopathic pulmonary fibrosissource ↗
▲Quarterly UpdateAfirmaCorporate
Expected Q4 2017 genomic test volume for Afirma and Percepta classifiers approximately 7,100 tests
thyroid cancersource ↗
▲Quarterly UpdatePerceptaCorporate
Expected Q4 2017 genomic test volume for Afirma and Percepta classifiers approximately 7,100 tests
lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How VCYT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 80%
Small Cap(rank 526 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every VCYT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| docetaxel | metastatic prostate cancer | Phase 3 | 2026-06-01 | 634 patients, median follow-up of 5.6 yearsRead More | ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bhanji MunaDirector | Sell | -1,864 40,854 held | $43.70 | 10/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VCYT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.9 % (216.7 %) | 18.68 M | 318.00 K | 76.96% ( 138.30 K) |
VCYT Institutional Ownership Trends
VCYT Short Interest
Shares sold short, counted twice a month.
12.9%
Short % of Float
of tradable shares sold short
10.2M
Shares Sold Short
+21.1% vs prior count
5.9 High
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VCYT ranks across every disease it competes in
Competitive Position is a premium feature
See how VCYT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVCYT News
VCYTVeracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
Veracyte, Inc. has announced that it will release its financial results for the second quarter of 2026 on July 30, 2026. Following the release, company management will host a conference call and webcast to discuss the results and provide a business update. The call is scheduled for 4:30 p.m. Eastern Time.
Read more →VCYTENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
The ENZAMET trial presented at the ASCO Annual Meeting demonstrates that Veracyte's Decipher Prostate test can effectively identify which men with metastatic prostate cancer will benefit from adding chemotherapy to standard hormonal therapy. This represents the first Level 1B evidence for genomic-guided treatment decisions in this context. The findings also reinforce the test's utility in high-risk localized prostate cancer.
Read more →VCYTLandmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
The OPTIMA trial has demonstrated that Veracyte's Prosigna test can effectively guide chemotherapy decisions for patients with early-stage, ER-positive HER2-negative breast cancer. The trial found that more than two-thirds of participants could safely avoid chemotherapy based on their Prosigna test results. This represents a significant shift in treatment approaches, allowing for reduced side effects and improved patient outcomes.
Read more →VCYTOPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Veracyte, Inc. announced that data from the OPTIMA and ENZAMET trials will be presented at the ASCO 2026 Annual Meeting. The OPTIMA trial focuses on using the Prosigna test to guide chemotherapy decisions in high-risk breast cancer patients. The ENZAMET trial evaluates the Decipher test's ability to predict treatment benefits in metastatic prostate cancer. These findings may significantly influence treatment personalization and decision-making in oncology.
Read more →VCYTVeracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
Veracyte has announced an upcoming investor call scheduled for June 1, 2026, where they will discuss findings from the ASCO conference. The call aims to provide insights into the company's latest research and developments. Further details about the findings have not been disclosed in the announcement.
Read more →VCYT▲ +8.4%on this newsshared move
Veracyte to Participate in Upcoming June 2026 Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) has announced its participation in upcoming investor conferences. The company will provide live audio webcasts of its presentations, which will be accessible on their website. This initiative reflects Veracyte's ongoing commitment to engage with investors and showcase its advancements in cancer diagnostics.
Read more →VCYTVeracyte to Participate in Upcoming Investor Conferences
Veracyte is set to participate in upcoming investor conferences, indicating its ongoing engagement with the investment community. The article does not provide specific details about the conferences or the topics to be discussed. This participation may enhance Veracyte's visibility among investors and stakeholders.
Read more →VCYTVeracyte Announces First Quarter 2026 Financial Results
Veracyte's announcement of its first quarter 2026 financial results is notably lacking in detail. The article does not provide any insights into the company's financial performance or future projections. This absence of information may raise concerns among stakeholders regarding the company's transparency and strategic direction.
Read more →VCYT▲ +5.7%on this newsshared move
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
Veracyte has announced the date for its first quarter 2026 financial results release, which is set for May 5, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided at that time.
Read more →VCYT▲ +8.5%on this news
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
Veracyte, Inc. reported strong financial results for Q4 and full year 2025, with total revenue reaching $140.6 million in Q4, a 19% increase year-over-year. The company highlighted significant growth in its testing revenue and net income, which surged by 705%. Looking ahead, Veracyte anticipates continued growth in 2026, driven by new product launches and an expected revenue increase of 10% to 13%.
Read more →VCYTVeracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
Veracyte, Inc. will present over 15 abstracts at the 2026 ASCO GU Symposium, focusing on its urology portfolio, including studies on prostate and bladder cancers. The presentations will feature insights from phase II trials and real-world data, showcasing the impact of Decipher and TrueMRD tests on clinical decision-making and treatment strategies. The conference is scheduled for February 26-28 in San Francisco.
Read more →VCYTVeracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Veracyte, Inc. will announce its financial results for Q4 and full-year 2025 on February 25, 2026. Following the release, management will hold a conference call and webcast to discuss the results and provide a business update. The call is scheduled for 4:30 p.m. ET and will be accessible via the company's website.
Read more →VCYTVeracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Veracyte, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be accessible via live audio webcasts on the company's website, with replays available for 30 days. Veracyte aims to transform cancer care through its advanced diagnostics platform.
Read more →VCYT▲ +13.1%on this news
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform Grew full-year revenue to between $3
Veracyte, a cancer diagnostics company, announced its preliminary financial results for 2023, reporting a revenue increase of 21% to between $358 million and $359 million. The company has also entered a definitive agreement to acquire C2i Genomics, enhancing its diagnostic platform with minimal residual disease capabilities. This acquisition is expected to aid in monitoring cancer treatment efficacy and improve patient outcomes. Veracyte anticipates a revenue growth of 10% to 12% for 2024, although certain revenue lines may decline.
Read more →VCYTVeracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth SOUTH SAN FRANCISCO, Calif., July 12, 2021 --- Veracyte, Inc. (Nasdaq VCYT), a global genomic diagnostics company, today announced the appoin
Read more →VCYTVeracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cance
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference
Read more →VCYTVeracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock SAN FRANCISCO, Calif. (BUSINESS WIRE) February 4, 2021 Veracyte, Inc. (Nasdaq: VCYT) (the Company ) today announced the pricing of an underwritten public offering of 7,432,433 shares of it
Read more →VCYTVeracyte To Acquire Decipher Biosciences Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expec
Veracyte To Acquire Decipher Biosciences Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth Tina Nova, Ph.D., Decipher Biosciences presid
Read more →VCYTVeracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) August 4, 2020 Veracyte, Inc. (Nasdaq: VCYT) (the Company ) today announced the pricing of an underwritten public offering of 6,000,000 shares of its co
Read more →VCYTVeracyte Announces Third Quarter 2019 Financial Results and Business Progress Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swa
Veracyte Announces Third Quarter 2019 Financial Results and Business Progress Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swab Test for Lung Cancer Early Detection Conference Call
Read more →About Veracyte, Inc.
Headquarters6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next VCYT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime